This technology is investigational and has not been approved or cleared by any regulatory authority. Statements describe development focus and design intent only and do not represent clinical performance or outcomes.
Designed Around the Realities of CTO Crossing
Predictable
crossing
Developed with a focus on predictability in treating complex occlusions.
Broader access to more
complex cases
Built to support access across a wider range of complex lesions.
Intraluminal-first
option
Designed to support true lumen crossing strategies
Crossing Comes First
Crossing occlusive disease is a critical prerequisite to introducing any follow-on therapy.
Crossing complex lesions remains one of the most challenging steps in endovascular intervention.
ProSonic™ address this bottleneck, allowing intraluminal access through complex occlusive disease before final treatment decisions are made.
Ultrasonic Mechanism of Action
The following sequence describes design intent and observed behaviour under evaluation, not clinical outcomes.
Position
ProSonic™’s tip is positioned adjacent to the calcified occlusive cap. This non-contact positioning provides space for acoustic streaming and cavitation to occur without mechanical energy damping.
Activation
High-frequency ultrasonic activity, generates high-speed pressure (shock) waves at the tip of the device, with acoustic effects interacting with occlusive disease under clinical evaluation.
Orbital Modulation
Axial and radial tip movement and cavitation interact as ultrasonic energy propagates, producing a dynamic acoustic pattern along the intended path within the occlusive segment.
Preparation
The combined axial and radial motion establishes a localised ultrasonic energy field along the intended path, shaping the vessel environment ahead of subsequent procedural steps.
Connect With Versono
Versono is developing an intravascular ultrasonic platform focused first on crossing complex peripheral chronic total occlusions, using a distinct mode of action based on proprietary axial and radial ultrasonic energy delivery.
Development is evidence-led and phased, with an initial focus on crossing and a longer-term platform vision informed by clinical evaluation.
We are now welcoming investor interest as the company enters its next stage of development.
